Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

ABSTRACT:

SUBMITTER: Andtbacka R 

PROVIDER: S-EPMC4292568 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature